Targeting DYRK2 to kill leukemia stem cells in CML

Who could benefit from this research

What this research studies

If successful, this work could lead to new strategies that, alongside existing therapies, reduce the stubborn leukemia stem cells in CML. The project will explore genetic and drug-based methods to stabilize DYRK2, hoping to slow or stop disease progression. Researchers will study how DYRK2 controls self-renewal and survival in leukemic stem cells, using models and experiments designed to translate findings toward frontline therapies that may extend treatment-free remission.

Why it matters

Where this research is happening

• Baylor College of Medicine
  Houston, United States Active

Researchers

• Principal investigator: Lacorazza, Daniel — Baylor College of Medicine
• Study coordinator: Lacorazza, Daniel

Related research

Other NIH-funded projects on the same topics.

• Chronic myeloid leukemia: how T cells and leukemia stem cells interact during treatment

  This NIH grant explores how immune cells and stubborn leukemia stem cells interact during therapy to better predict if patients can stay off treatment.

  NIH research Northwestern University · Chicago, United States · NIH-11418370

• Why chronic myeloid leukemia sometimes resists treatment and how to improve TKI care

  This project looks at why some people with chronic myeloid leukemia respond differently to tyrosine kinase inhibitor drugs and aims to help more patients get deeper, longer-lasting remissions.

  NIH research University of California-Irvine · Irvine, United States · NIH-11306059

• Targeting a specific protein to eliminate leukemia stem cells in chronic myeloid leukemia.

  This study is looking at a new way to help people with chronic myeloid leukemia (CML) by focusing on a protein called DYRK2, which could help make leukemia stem cells less likely to survive, so patients might be able to stop their current treatments without their cancer coming back.

  NIH research Baylor College of Medicine · Houston, United States · NIH-11109689

• Understanding how some patients with chronic myeloid leukemia can remain healthy without treatment

  This study is looking into why some people with chronic myeloid leukemia can stay healthy without taking their medication, using mice to find out what helps them maintain remission, which could lead to better ways to manage the condition and lessen the need for long-term treatment.

  NIH research University of California-Irvine · Irvine, United States · NIH-11078332

• Improving treatment for chronic myeloid leukemia with targeted therapies

  This study is looking for ways to help people with chronic myeloid leukemia (CML) respond better to their main treatment, tyrosine kinase inhibitors (TKIs), especially during the first year after they are diagnosed, so that more patients can achieve a lasting remission and possibly a cure.

  NIH research University of California-Irvine · Irvine, United States · NIH-11016818

• Targeting a specific protein to treat chronic myeloid leukemia

  This study is testing a new small protein that could help stop a key protein linked to chronic myeloid leukemia from working against you, and if it works, it might offer a fresh treatment option for patients like you.

  NIH research University of Utah · Salt Lake City, United States · NIH-11001839

About this research

1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
3. For full project details, budget, and progress reports, visit the official NIH RePORTER page.